Mostly they differ in the timing and dosage of the components that make up the drug combination. Oncologists select the protocol based on their experiences more than anything else I think. Personal preference maybe. By and large I don't think there is much difference clinically in the outcomes depending on which protocol is used. Lot of experimentation with this drug combination in Oncology practice. Seems its more likely they add bevacizumab now a days to one of these FOLFOX protocols which does seem to make a difference to many.
Have a look at the following about FOLFOX: https://www.sciencedirect.com/topics/me ... try/folfox
DW 53 dx Jun 2013
CT mets Liver Spleen lung. IVb CEA~110
Jul 2013 Sig Resct
8/13 FolFox,Avastin 12Tx mild sfx, Ongoing 5-FU Avastin every 3 wks.
CEA: good marker
7/7/14 CT Can't see the spleen Mets.
8/16/15 CEA Up, CT new abdominal mets. Iri, 5-FU, Avastin every 2 wks.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen
5/2/17 Failed second trial, Hospitalized 15 days 5/11. Home Hospice 5/26, at peace 6/4/2017